Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
2 hedge funds and large institutions have $341K invested in Impel Pharmaceuticals Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 30 closing their positions.
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
71.98% less ownership
Funds ownership: 71.98% → 0% (-72%)
94% less funds holding
Funds holding: 32 → 2 (-30)
95% less capital invested
Capital invested by funds: $7.35M → $341K (-$7.01M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 30
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
-$1.78M |
| 2 |
NA
NVP Associates
Menlo Park,
California
|
-$1.32M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
-$1.24M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.24M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$217K |
IMPL Hedge Fund Activity: Q4 2023 in Review
2 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q4 2023, worth a combined $341K — down 95% from $7.35M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of IMPL and 0 opened new positions — a net loss of 30 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Kohlberg Kravis Roberts & Co, exiting entirely with an estimated $1.78M sold.
- 2 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q4 2023, down from 32 in Q3 2023.
- Funds reported $341K of Impel Pharmaceuticals Inc. Common Stock stock for Q4 2023, down 95% quarter-over-quarter.
- 0 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q4 2023 and 30 closed out, a net change of -30 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock seller in Q4 2023 was Kohlberg Kravis Roberts & Co, an estimated $1.78M sold.
Based on aggregated 13F filings for Q4 2023.